{"name":"Nordic Lymphoma Group","slug":"nordic-lymphoma-group","ticker":"","exchange":"","domain":"","description":"The Nordic Lymphoma Group is a collaborative research organization focused on advancing the treatment of lymphoma through clinical trials and research initiatives. With a strong emphasis on innovative therapies, the group aims to improve patient outcomes and contribute to the global understanding of lymphoma.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"R-pola-mini-CHP","genericName":"R-pola-mini-CHP","slug":"r-pola-mini-chp","indication":"Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients","status":"phase_3"}]}],"pipeline":[{"name":"R-pola-mini-CHP","genericName":"R-pola-mini-CHP","slug":"r-pola-mini-chp","phase":"phase_3","mechanism":"R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity.","indications":["Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"PR Newswire","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQXJCOV8ybXhCQm1ORmw4X3h2ZDg5d3lua2FJVjlCZExDenNzZVJTU04wd2xkU2Rac3IxMWEyaHNYTmpqX2NQREd1VURIdVF6LUhzOEYwWloxV1VwOGxOQUxadF90VlNPVFA2Q2pPM3FBWF9ETUM4aDF6SEYzR2t4djVjZHY3OXdtQ05z?oc=5","date":"2024-07-03","type":"regulatory","source":"The Lancet","summary":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial - The","headline":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOR21GamdYclBPZ2tLbWwya1ZVUi1pUDFHR1hkWjZ0TVlNWUJ4V3JrMkw3YlI5UzNPQk11UEhSVmFIWERtRjBNd3doVlI4WjNsMGdxUGltY3IwZUd2Tks1ZjZPZkx2bjBfQm1kMG9vc0lrOExHZ3RoUmVaSjNneE1aY3pYN01hMl8tME5NczhaclNKZUVEeE1oRnBKWDh5NXlMNUlsc1lsV0dVdmFF?oc=5","date":"2024-03-25","type":"pipeline","source":"Manufacturing Chemist","summary":"Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs - Manufacturing Chemist","headline":"Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE53OGhEZGNrX2NBcnlkd3VKR2RBeTREVTlmZF9ucFRGRjdRb3ZBRmNqYzhzclhjMmpIb0pnaWhxQ295WWM0S2lWNFBha0U3VjVkVDZrbjB6YnBUUHhxZWNZ?oc=5","date":"2023-11-13","type":"trial","source":"Nature","summary":"Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study | Blood Cancer Journal - Nature","headline":"Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort stud","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQNkR2N3lvNENsQXhRMWQ3WUdXWUtsc3NIZVhRVTFCUnZMLVhyYi1ON0IwUDAtZWlyanBMaG02aTRDS2RLRzlKdXBFcHpmQjNuTTN2LTN0VHZhMjA4N3lJZFYydzVLay15N0Z4NkVCdjRWUlo2SXZxQXVmZWNYUC1uUWpzSTJkS1ZYeVpfM0QyUmtONlNn?oc=5","date":"2022-12-13","type":"deal","source":"pharmaphorum","summary":"Nordic Nanovector board resigns en masse as merger bid fails - pharmaphorum","headline":"Nordic Nanovector board resigns en masse as merger bid fails","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNR0xiRjJTaEVhMTZPYzEwVmE1UVZlUHNmZUFUQVBLZWFMZWY0NXJRai1PMmh0VG91dWMxREpVRWRxSHhGYm5XRjUxclFfRVFpcERJaFNndmZTU1d2NFJqakpPMl9MWjFGTjc2akVQTnIxNjNxNXM0OHo2bzJPZ01IQlVqd3pEVGtMVzJ3WVVEdVpEOWgzcU5Gb1NoUnFJN2dnYVExM1RfcGFuejZzMGZ4dmVGLXFfVTNYNzFZZWFKWGdiU2d5eUlV?oc=5","date":"2019-09-06","type":"regulatory","source":"Hematology Advisor","summary":"M7-FLIPI Score Not Predictive of Outcomes in Chemo-Free Regimens for Follicular Lymphoma - Hematology Advisor","headline":"M7-FLIPI Score Not Predictive of Outcomes in Chemo-Free Regimens for Follicular Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE01UnByZXA0bjdkdndKZzJub0I0X2JPenFxOFVnNWR2UVBFdWdRa1I1UWJmWVRJNF9JSWNSR3Fzd0RmMERRbVF3N0FBQldBczhvWm9ubG55STgtRnQ3S203ajltcTlNWWY4WHh2OHNZQ2NVdU5P?oc=5","date":"2019-01-29","type":"trial","source":"Wiley","summary":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study - Wiley","headline":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete re","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPaV9CRTFxcUtVNUlDLWxNMFE0WHczSmtnaUdxcEJUYWZoZG44aF91R2sycVFBa1NIdUk1dWRacmdvRnRuU292ZHlUWEtZWHpWWWdPb0ZVYUtydjZzRy1xMjBpS000SHZBOU1mOUN6dThScDNFQXlCRGJnMDA0Q18xSkRNY2lQUFQzT2Z4ai13aGp1aEtkWWhOZWNPWUkxdld4RWg0MDZBajFaa2VLY1FUNE5rM0tpRURRT3dqY3VxWQ?oc=5","date":"2013-09-03","type":"pipeline","source":"Tidsskrift for Den norske legeforening","summary":"High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment - Tidsskrift for Den norske legeforening","headline":"High-dose therapy with autologous stem cell support for lymphoma – from experimental to standard treatment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}